A.P. Pharma To Present APF530 Patient-Satisfaction Data From Phase 3 Study

A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that the Company will present patient-satisfaction data from its Phase 3 trial of APF530 at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) International Symposium. The MASCC/ISOO 2012 International Symposium focuses on the clinical management of supportive care in oncology and will be held in New York City June 28 – 30. APF530 is the Company’s lead product candidate being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).

Presentation details are as follows:

Title:			Patient satisfaction with control of emesis following chemotherapy: comparison of APF530, a subcutaneous extended-release formulation of granisetron versus intravenous palonosetron
Authors:			Rebecca Clark-Snow, Veena Charu, Nashat Gabrail, Ronald Yanagihara, Martin Rosenberg, Erin O’Boyle, John Barr
Abstract No.:			1109
Presentation:			June 29, 2012, Poster Session II

The full abstract is available on the MASCC/ISOO website, here.

About APF530

A.P. Pharma's lead product, APF530, is in development for the prevention of both acute-onset and delayed-onset chemotherapy-induced nausea and vomiting (CINV). APF530 contains the 5-HT3 antagonist, granisetron, formulated in the Company’s proprietary Biochronomer™ drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Intravenous and oral formulations containing granisetron are approved for the prevention of acute-onset CINV, but not delayed-onset CINV. Granisetron was selected because it is widely prescribed by physicians based on a well-established record of safety and efficacy.

1 2 Next › Last »